184 related articles for article (PubMed ID: 18753122)
1. The significance of low-level plasma HIV viral load on COBAS TaqMan HIV-1 assays for patients with undetectable plasma viral load on COBAS Amplicor monitor version 1.5.
Manavi K
HIV Clin Trials; 2008; 9(4):283-6. PubMed ID: 18753122
[TBL] [Abstract][Full Text] [Related]
2. Low-level viremia associated with the use of TaqMan assay.
Szabo S; Moffett LE; Cantwell-McNelis K; James CW; Joseph A
J Int Assoc Physicians AIDS Care (Chic); 2010; 9(4):203-5. PubMed ID: 20530465
[TBL] [Abstract][Full Text] [Related]
3. Cobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level.
Taylor N; Grabmeier-Pfistershammer K; Egle A; Greil R; Rieger A; Ledergerber B; Oberkofler H
PLoS One; 2013; 8(8):e74024. PubMed ID: 24023696
[TBL] [Abstract][Full Text] [Related]
4. Viral load assay sensitivity and low level viremia in HAART treated HIV patients.
Verhofstede C; Van Wanzeele F; Reynaerts J; Mangelschots M; Plum J; Fransen K
J Clin Virol; 2010 Apr; 47(4):335-9. PubMed ID: 20138803
[TBL] [Abstract][Full Text] [Related]
5. Improved Performance of COBAS AmpliPrep/COBAS TaqMan Version 2.0 Assay Over Amplicor Monitor Version 1.5 in the Quantification of HIV-1 RNA Viral Load in Abuja, Nigeria.
Abubakar A; Ndembi N; Ogbanufe O; Inalegwu A; Wilson S; Ebagua I; Peters S; Chime C; Dakum P; Abimiku AG
Curr HIV Res; 2015; 13(4):262-7. PubMed ID: 25613132
[TBL] [Abstract][Full Text] [Related]
6. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay.
Lima V; Harrigan R; Montaner JS
J Acquir Immune Defic Syndr; 2009 May; 51(1):3-6. PubMed ID: 19247185
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the rate and size of HIV-1 viral load blips with Roche COBAS TaqMan HIV-1 versions 1.0 and 2.0 and implications for patient management.
Garrett NJ; Apea V; Nori A; Ushiro-Lumb I; Oliver AR; Baily G; Clark DA
J Clin Virol; 2012 Apr; 53(4):354-5. PubMed ID: 22261125
[TBL] [Abstract][Full Text] [Related]
8. Short communication: east meets west: a description of HIV-1 drug resistance mutation patterns of patients failing first line therapy in PEPFAR clinics from Uganda and Nigeria.
Crawford KW; Wakabi S; Kibuuka H; Magala F; Keshinro B; Okoye I; Akintunde E; Hamm TE
AIDS Res Hum Retroviruses; 2014 Aug; 30(8):796-9. PubMed ID: 24798614
[TBL] [Abstract][Full Text] [Related]
9. [Utilities and limitations of a real-time PCR based assay for HIV-1 RNA quantification].
Yotsumoto M; Yamamoto Y; Amano K; Fukutake K
Rinsho Byori; 2010 Feb; 58(2):124-30. PubMed ID: 20229810
[TBL] [Abstract][Full Text] [Related]
10. High correlation between the Roche COBAS® AmpliPrep/COBAS® TaqMan® HIV-1, v2.0 and the Abbott m2000 RealTime HIV-1 assays for quantification of viral load in HIV-1 B and non-B subtypes.
Karasi JC; Dziezuk F; Quennery L; Förster S; Reischl U; Colucci G; Schoener D; Seguin-Devaux C; Schmit JC
J Clin Virol; 2011 Nov; 52(3):181-6. PubMed ID: 21813320
[TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays.
Damond F; Roquebert B; Bénard A; Collin G; Miceli M; Yéni P; Brun-Vezinet F; Descamps D
J Clin Microbiol; 2007 Oct; 45(10):3436-8. PubMed ID: 17715371
[TBL] [Abstract][Full Text] [Related]
12. Concordance of HIV-1 RNA Values by Amplicor and TaqMan 2.0 in Patients With Confirmed Suppression in Clinical Trials.
Garner W; White K; Szwarcberg J; McCallister S; Zhong L; Wulfsohn M
Clin Infect Dis; 2016 Apr; 62(7):929-934. PubMed ID: 26689956
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of the Cobas Amplicor HIV-1 Monitor Ultrasensitive Test, the new Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitor Ultrasensitive Test and the Versant HIV RNA 3.0 assays for quantitation of HIV-1 RNA in plasma samples.
Berger A; Scherzed L; Stürmer M; Preiser W; Doerr HW; Rabenau HF
J Clin Virol; 2005 May; 33(1):43-51. PubMed ID: 15797364
[TBL] [Abstract][Full Text] [Related]
14. Fully automated quantification of human immunodeficiency virus (HIV) type 1 RNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system.
Schumacher W; Frick E; Kauselmann M; Maier-Hoyle V; van der Vliet R; Babiel R
J Clin Virol; 2007 Apr; 38(4):304-12. PubMed ID: 17329164
[TBL] [Abstract][Full Text] [Related]
15. Mutations to the probe of Cobas TaqMan HIV-1 ver. 1.0 assay causing undetectable viral load in a patient with acute HIV-1 infection.
Yotsumoto M; Shinozawa K; Yamamoto Y; Sugiura W; Miura T; Fukutake K
J Infect Chemother; 2011 Dec; 17(6):863-5. PubMed ID: 21671012
[TBL] [Abstract][Full Text] [Related]
16. Introduction of TaqMan HIV-1 assay increased unnecessary drug resistance testing.
Gatanaga H; Oowa M; Oka S
AIDS Patient Care STDS; 2010 Apr; 24(4):203-4. PubMed ID: 20377436
[No Abstract] [Full Text] [Related]
17. Evaluation of quantification of HIV-1 RNA viral load in plasma and dried blood spots by use of the semiautomated Cobas Amplicor assay and the fully automated Cobas Ampliprep/TaqMan assay, version 2.0, in Kisumu, Kenya.
Ouma KN; Basavaraju SV; Okonji JA; Williamson J; Thomas TK; Mills LA; Nkengasong JN; Zeh C
J Clin Microbiol; 2013 Apr; 51(4):1208-18. PubMed ID: 23390278
[TBL] [Abstract][Full Text] [Related]
18. Undetectable HIV-1 RNA load with the Cobas TaqMan v1.0 in a patient diagnosed at the time of primary HIV-1 infection.
Ghosn J; Galimand J; Meyer L; Descamps D; Vabret A; Deveau C; Yéni P; Goujard C; Rouzioux C; Chaix ML;
J Med Virol; 2010 Nov; 82(11):1816-8. PubMed ID: 20872706
[TBL] [Abstract][Full Text] [Related]
19. Multi-site clinical evaluation of the Xpert(®) HIV-1 viral load assay.
Jordan JA; Plantier JC; Templeton K; Wu AH
J Clin Virol; 2016 Jul; 80():27-32. PubMed ID: 27135387
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.
Soulie C; Grudé M; Descamps D; Amiel C; Morand-Joubert L; Raymond S; Pallier C; Bellecave P; Reigadas S; Trabaud MA; Delaugerre C; Montes B; Barin F; Ferré V; Jeulin H; Alloui C; Yerly S; Signori-Schmuck A; Guigon A; Fafi-Kremer S; Haïm-Boukobza S; Mirand A; Maillard A; Vallet S; Roussel C; Assoumou L; Calvez V; Flandre P; Marcelin AG;
J Antimicrob Chemother; 2017 Aug; 72(8):2351-2354. PubMed ID: 28472307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
